Professor Anstee is an Honorary Consultant Hepatologist based at the Freeman Hospital where he has a particular specialist interest is the diagnosis and treatment of patients with Non-Alcoholic Fatty Liver Disease (NAFLD). This is an increasingly common, progressive liver disease that is strongly associated with features of the ‘metabolic syndrome’:
- including obesity
- type 2 diabetes mellitus
- high blood pressure
- high cholesterol
As chair of experimental hepatology in the Faculty of Medical Sciences at Newcastle University, Professor Anstee’s research is dedicated to improving the care of liver patients by advancing our understanding the biological causes of progressive liver disease and cirrhosis.
Professor Anstee trained in medicine at University College London where he was awarded First Prize in Medicine in the final MB BS examination (The Philip Seth Belasco & Douglas Cree Prize, 1997). His postgraduate specialist clinical training in Hepatology, Gastroenterology and General Medicine was undertaken in London, principally at the Liver and Anti-Viral Unit, St Mary’s Hospital (Imperial College Healthcare).
Professor Anstee has a particular sub-specialist interest in the treatment of liver disease related to diabetes, high cholesterol and obesity and leads the multidisciplinary regional ‘fatty liver’ service. His clinical expertise includes the management of patients with a range of acute and chronic liver conditions including:
- Non-Alcoholic Fatty Liver Disease (NAFLD) & Non-Alcoholic Steatohepatitis (NASH)
- Alcoholic Liver Disease
- Autoimmune Hepatitis
- Primary Biliary Cholangitis (PBC)
- Cirrhosis and its complications
- Liver Transplantation
When not working, Professor Anstee’s personal interests and hobbies include sailing and the theatre.
Professor Anstee is Chair of Experimental Hepatology in Newcastle University’s Faculty of Medical Sciences.
His translational research has extended “from the bench to the bedside” with a particular focus on the pathogenesis, diagnosis and treatment of Non-Alcoholic Fatty Liver Disease & Non-Alcoholic Steatohepatitis (NAFLD/NASH). He leads major international research efforts to develop new tests that will improve the diagnosis and risk-stratification of patients with liver disease.
Professor Anstee also serves as the Chief Investigator of the European NAFLD Registry as well as numerous ongoing clinical trials developing new medicines to treat patients with liver disease.
Fellowships and Memberships of Learned Societies:
- Royal College of Physicians of London (FRCP)
- Association of Physicians of Great Britain & Ireland (AoP, elected 2014)
- European Association for the Study of the Liver (EASL)
- American Association for the Study of the Liver (AASLD)
- British Association for the Study of the Liver (BASL)
- British Society of Gastroenterology (BSG)